Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 54 of the 54 references it cites were found in a registry or an index.
Abstract
A mouse model with liver-specific deletion of the NADPH-cytochrome P450 reductase (Cpr) gene (designated Alb-Cre/Cprlox mice) was generated and characterized in this study. Hepatic microsomal CPR expression was significantly reduced at 3 weeks and was barely detectable at 2 months of age in the Alb-Cre+/-/Cprlox+/+ (homozygous) mice, with corresponding decreases in liver microsomal cytochrome P450 (CYP) and heme oxygenase (HO) activities, in pentobarbital clearance, and in total plasma cholesterol level. Nevertheless, the homozygous mice are fertile and are normal in gross appearance and growth rate. However, at 2 months, although not at 3 weeks, the homozygotes had significant increases in liver weight, accompanied by hepatic lipidosis and other pathologic changes. Intriguingly, total microsomal CYP content was increased in the homozygotes about 2-fold at 3 weeks and about 3-fold at 2 months of age; at 2 months, there were varying degrees of induction in protein (1-5-fold) and mRNA expression (0-67-fold) for all CYPs examined. There was also an induction of HO-1 protein (nearly 9-fold) but no induction of HO-2. These data indicate the absence of significant alternative redox partners for liver microsomal CYP and HO, provide in vivo evidence for the significance of hepatic CPR-dependent enzymes in cholesterol homeostasis and systemic drug clearance, and reveal novel regulatory pathways of CYP expression associated with altered cellular homeostasis. The Alb-Cre/Cprlox mouse represents a unique model for studying the in vivo function of hepatic HO and microsomal CYP-dependent pathways in the biotransformation of endogenous and xenobiotic compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore these animals had dramatically decreased capacities to metabolize acetaminophen, phenobarbital, and testosterone despite having a 5-fold increase in total hepatic P450 content.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [313]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, liver-specific POR knockout mice created by cre/lox technology were grossly normal-developing, growing, and living as long as normal mice, and having normal reproductive capacity, indicating normal gonadal P450 function (312,313).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [313]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these mice had hepatomegaly, accumulated hepatic lipids, and had a 99% decrease in bile acids, 65% decrease in serum cholesterol, and 50% decrease in serum triglycerides.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [313]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Liver-specific knockout of POR in mice decreases the activities of hepatic drug-metabolizing enzymes (312, 313), thereby potentially rendering some drugs teratogenic.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [313]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Cytochrome P-450: Structure, Mechanism, and Biochemistry
de Montellano, O., & Paul, R. (1986) · Medical Entomology and Zoology · Cited by 2,663
THE HEME OXYGENASE SYSTEM:A Regulator of Second Messenger Gases
Maines, M. D. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.517 · Cited by 2,505
Cytochrome P450: Structure, mechanism, and biochemistry
Pryor, W. A. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(96)83807-x · Cited by 1,598
Carbon Monoxide: a Putative Neural Messenger
Verma, A., Hirsch, D. J., Glatt, C. E., Ronnett, G. V., & Snyder, S. H. (1993) · Science · doi:10.1126/science.7678352 · Cited by 1,563
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Immune System Impairment and Hepatic Fibrosis in Mice Lacking the Dioxin-Binding Ah Receptor
Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S. T., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., & Gonzalez, F. J. (1995) · Science · doi:10.1126/science.7732381 · Cited by 1,075
Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., & Bradfield, C. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6731 · Cited by 891
Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms
Porter, T. D., & Coon, M. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92717-1 · Cited by 678
Research works printed but not linked: 7
- 4. Black, S. D., and Coon, M. J. (1987) Adv. Enzymol. Relat Areas Mol. Biol. 60, 35-87
- 13. Pluck, A. (1996) Int. J. Exp. Pathol. 77, 269 -278
- 15. Gu, J., Zhang, Q.-Y., Genter, M. B., Lipinskas, T. W., Negishi, M., Nebert, D. W., and Ding, X. (1998) J. Pharmacol. Exp. Ther. 285, 1287-1295
- 17. Su, T., Bao, Z. P., Zhang, Q.-Y., Smith, T. J., Hong, J. Y., and Ding, X. (2000) Cancer Res. 60, 5074 -5079
- 19. Ding, X., and Coon, M. J. (1990) Mol. Pharmacol. 37, 489 -496
- 23. Su, T., Sheng, J. J., Lipinskas, T. W., and Ding, X. (1996) Drug Metab. Dispos. 24, 884 -890
- 34. Maines, M. D. (2000) Cell Mol. Biol. 46, 573-585
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“In contrast, liver-specific knockout of por leads to phenotypically and reproductively normal mice that accumulate hepatic lipids and have a drastically diminished capacity for hepatic drug metabolism (Gu et al., 2003; Finn et al., 2007).”
BackgroundThe Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
The Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
“2 POR P450 (cytochrome) oxidoreductase Conditional KO (liver specific) Increased liver weight and fatty liver (506,507)”
BackgroundCytochrome P450s and other enzymes in drug metabolism and toxicity
Guengerich, F. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080112 · Cited by 624
Gachon, F., Olela, F. F., Schaad, O., Descombes, P., & Schibler, U. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.015 · Cited by 512
“For example, a similar phenotype has been observed in mice with a liver-specific disruption of the Por gene ( Gu et al., 2003; Henderson et al., 2003).”
BackgroundHuang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
“…al. 2003), apparently due to disruption of extrahepatic P450 enzymes, as liver-specific knockout of Por yields phenotypically and reproductively normal mice that accumulate hepatic lipids and have a remarkably diminished capacity for hepatic drug metabolism (Gu et al. 2003; Henderson et al. 2003).”
BackgroundCyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
Takahashi, S., Fukami, T., Masuo, Y., Brocker, C. N., Xie, C., Krausz, K. W., Wolf, C. R., Henderson, C. J., & Gonzalez, F. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m071183 · Cited by 313
“reductase (22), which decreased all CYPs activities, were found to have marked differences in a bile acid compositions including lower MCA and taurine-conjugated MCA as compared to their wild-type”
MethodPreclinical experimental models of drug metabolism and disposition in drug discovery and development
Zhang, D., Luo, G., Ding, X., & Lu, C. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.10.004 · Cited by 309
Self-citationNADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & Hollenberg, P. F. (2015) · Cytochrome P450 · doi:10.1007/978-3-319-12108-6_5 · Cited by 257
Lorbek, G., Lewinska, M., & Rozman, D. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08432.x · Cited by 196
Variation in CYP2A6 Activity and Personalized Medicine
Tanner, J.-A., & Tyndale, R. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm7040018 · Cited by 172
“The fundamental role of POR in CYP enzyme function is illustrated by the substantial decrease in CYP activity in hepatic POR-deficient mice [82,83].”
BackgroundFukami, M., Horikawa, R., Nagai, T., Tanaka, T., Naiki, Y., Sato, N., Okuyama, T., Nakai, H., Soneda, S., Tachibana, K., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0810 · Cited by 155
“By contrast, liverspecific Por knockout mice show a drastically reduced pentobarbital clearance (46).”
BackgroundNADPH–Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology
Riddick, D. S., Ding, X., Wolf, C. R., Porter, T. D., Pandey, A. V., Zhang, Q., Gu, J., Finn, R. D., Ronseaux, S., McLaughlin, L. A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048991 · Cited by 164
“Department of Health, Albany, NY) independently published their studies on the conditional deletion of POR expression in mouse liver (Gu et al., 2003; Henderson et al., 2003).”
BackgroundSelf-citationGilep, A. A., Sushko, T. A., & Usanov, S. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.06.021 · Cited by 146
Gao, J., & Xie, W. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035568 · Cited by 146
“Mouse models with liver-specific deletion of CPR were generated by two independent groups (Gu et al., 2003; Henderson et al., 2003).”
Function of human cytochrome P450s: Characterization of the orphans
Guengerich, F. P., Wu, Z., & Bartleson, C. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.079 · Cited by 133
“ablation of NADPH-P450 reductase in mouse liver in conditional knock-out animals, which effectively eliminates the function of all hepatic P450s, appears to have only a very limited physiological effect beyond the accumulation of cholesterol [11,12].”
BackgroundGomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 125
Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Edwardson, D. W., Narendrula, R., Chewchuk, S., Mispel-Beyer, K., Mapletoft, J., & Parissenti, A. M. (2015) · Current Drug Metabolism · doi:10.2174/1389200216888150915112039 · Cited by 145
Genetic and clinical features of P450 oxidoreductase deficiency
Scott, R. R., & Miller, W. L. (2008) · Hormone Research in Paediatrics · doi:10.1159/000114857 · Cited by 115
“The lethality appears to be due to extrahepatic POR deficiency, since a liver-specific POR knockout mouse has a severely impaired drug metabolism but normal development and reproductive capacity [”
BackgroundStructural diversity of cytochrome P450 enzyme system
Omura, T. (2010) · The Journal of Biochemistry · doi:10.1093/jb/mvq001 · Cited by 112
Gu, J., Cui, H., Behr, M. J., Li, Z., Zhang, Q.-Y., Yang, W., Hinson, J., & Ding, X. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007898 · Cited by 114
“We and others (Gu et al., 2003; Henderson et al., 2003) have recently developed one such model (named the liver-specific Cpr-null mouse, and referred to as Null mouse in the present article), in which the gene encoding NADPH-cytochrome P450 reductase (Cpr), the obligate redox partner for all microsomal P450s, is delet…”
InfluentialSelf-citationAgrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833e0cb5 · Cited by 104
Guengerich, F. P., & Cheng, Q. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003525 · Cited by 103
“, 2002), although the exact reason is not clear [attenuation of the reductase in selected organs in mice has a relatively modest effect (Gu et al., 2003)].”
BackgroundGandhi, C. R., Chaillet, J. R., Nalesnik, M. A., Kumar, S., Dangi, A., Demetris, A. J., Ferrell, R., Wu, T., Divanovic, S., Stankeiwicz, T., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.008 · Cited by 99
Hart, S. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X.-B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f2f121 · Cited by 98
Pharmacogenomics of human P450 oxidoreductase
Pandey, A. V., & Sproll, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00103 · Cited by 92
“The liver-specific knockout of POR produces mice with lower metabolism and lipid accumulation (Gu et al., 2003; Henderson et al., 2003; Porter et al., 2011).”
BackgroundWeng, Y., Fang, C., Turesky, R. J., Behr, M. J., Kaminsky, L. S., & Ding, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1006 · Cited by 101
“The liver-Cpr -null (8) and Cpr mice (transgenic”
BackgroundInfluentialSelf-citationFinn, R. D., McLaughlin, L. A., Ronseaux, S., Rosewell, I. R., Houston, J. B., Henderson, C. J., & Wolf, C. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803496200 · Cited by 97
Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway
Finn, R. D., Henderson, C. J., Scott, C. L., & Wolf, C. R. (2008) · Biochemical Journal · doi:10.1042/bj20080740 · Cited by 98
Consequences of POR mutations and polymorphisms
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., Morrissey, K., & Giacomini, K. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.022 · Cited by 88
“By contrast, liver-specific POR knockout mice were grossly normal, had a normal life span and had normal reproductive capacity, indicating normal gonadal P450 function (Gu et al., 2003; Henderson et al., 2003).”
BackgroundReed, L., Arlt, V. M., & Phillips, D. H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy058 · Cited by 100
“POR null) generated by cross-breeding CCSP-rtTA/tetO-Cre mice and Cprlox/lox mice that allows doxycycline-inducible lung-specific Cpr deletion (80), and a liver-Cpr-null mouse generated by breeding pairs of hemizygous Alb-Cre transgenic mice, with Cre driven by the albumin promoter that lack POR expression in the live…”
BackgroundDostálek, M., Hardy, K. D., Milne, G. L., Morrow, J. D., Chen, C., Gonzalez, F. J., Gu, J., Ding, X., Johnson, D. A., Johnson, J. A., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802447200 · Cited by 89
Self-citationLi, L., Wei, Y., Winkle, L. S. V., Zhang, Q., Zhou, X. H., Hu, J., Xie, F., Kluetzman, K., & Ding, X. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184671 · Cited by 82
“lox)] mice (Gu et al., 2003), which have tissue-specific deletion of the”
BackgroundSelf-citationDeletion of Microsomal Cytochrome b5 Profoundly Affects Hepatic and Extrahepatic Drug Metabolism
McLaughlin, L. A., Ronseaux, S., Finn, R. D., Henderson, C. J., & Wolf, C. R. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064246 · Cited by 84
“A similar increase in P450 expression was also observed when hepatic POR was conditionally deleted (Gu et al., 2003; Henderson et al., 2003), which in this latter case seems to be due to activation of the constitutive androstane receptor and, to a lesser degree, the pregnane X receptor by accumulated polyunsaturated f…”
BackgroundLam, V., Takechi, R., Hackett, M. J., Francis, R., Bynevelt, M., Celliers, L. M., Nesbit, M., Mamsa, S., Arfuso, F., Das, S., et al. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001358 · Cited by 80
Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity
Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., Li, L., Liu, L., Qi, X., Zhang, Y., et al. (2008) · Kidney International · doi:10.1038/ki.2008.103 · Cited by 77
Self-citationEffects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Naik, A., Belič, A., Zanger, U. M., & Rozman, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00002 · Cited by 72
“The liver conditional Por knockout mice display hepatomegaly, hepatic steatosis, and a reduced capacity of drug metabolism (Gu et al., 2003).”
BackgroundWu, L., Gu, J., Cui, H., Zhang, Q.-Y., Behr, M. J., Fang, C., Weng, Y., Kluetzman, K., Swiatek, P. J., Yang, W., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073353 · Cited by 71
“The in vivo function of hepatic CPR in adult mice has also been examined in liver-specific Cpr-null (liver-Cpr-null or Alb-Cre/Cprlox) mouse models (Gu et al., 2003; Henderson et al., 2003).”
BackgroundMethodResultSelf-citationConditional knockout of the mouse NADPH‐cytochrome p450 reductase gene
Wu, L., Gu, J., Weng, Y., Kluetzman, K., Swiatek, P., Behr, M., Zhang, Q., Zhuo, X., Xie, Q., & Ding, X. (2003) · genesis · doi:10.1002/gene.10214 · Cited by 68
“One of these studies (Gu et al., 2003) used the Cprlox model described here, whereas the other (Henderson et al., 2003) used a model in which the conditional Cpr allele had a loxP-neo-loxP cassette in intron 4 and an additional loxP site in intron 15.”
BackgroundMethodSelf-citationKnockout of hepatic P450 reductase aggravates triptolide-induced toxicity
Xue, X., Gong, L., Qi, X., Wu, Y., Xing, G., Yao, J., Luan, Y., Xiao, Y., Li, Y., Wu, X., et al. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.05.003 · Cited by 68
Self-citationWeng, Y., Dirusso, C., Reilly, A. A., Black, P. N., & Ding, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504447200 · Cited by 75
Self-citationMegaraj, V., Ding, X., Fang, C., Kovalchuk, N., Zhu, Y., & Zhang, Q.-Y. (2014) · Chemical Research in Toxicology · doi:10.1021/tx4004769 · Cited by 67
Self-citationSheng, L., Ding, X., Ferguson, M., McCallister, M., Rhoades, R., Maguire, M., Ramesh, A., Aschner, M., Campbell, D., Levitt, P., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq304 · Cited by 63
“As mentioned in the ''Materials and Methods'' section, the Cpr lox/lox mouse is the WT control strain for future studies that will utilize tissue-specific Cpr-null mouse models, such as brain-Cpr-null (Conroy et al., 2010) and liver-Cpr-null models (Gu et al., 2003).”
MethodSelf-citationP450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity
Hart, S. N., & Zhong, X.-B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.439 · Cited by 70
“However, diets with low retinoic acids can only partially rescue the phenotypes [45,47] . In the case of liver-specific deletion of the POR gene, mice are reproductively and morphologically normal, but they show a profound decrease in the metabolism of steroids and drugs [ 48 ,49] . Interestingly, hepatocyte-specific…”
BackgroundElectron Transfer Partners of Cytochrome P450
Waskell, L. A., & Kim, J. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_2 · Cited by 92
Wang, X. J., CHAMBERLAIN, M., Vassieva, O., Henderson, C. J., & Wolf, C. R. (2005) · Biochemical Journal · doi:10.1042/bj20042087 · Cited by 65
Henderson, C. J., McLaughlin, L. A., & Wolf, C. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084616 · Cited by 60
“Deletion of POR had a major effect on both in vitro and in vivo metabolism although in vitro P450 activity was not completely ablated (10% residual activity) (Gu et al., 2003; Henderson et al., 2003).”
BackgroundInfluentialP450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity
Bissig, K., Han, W., Barzi, M., Kovalchuk, N., Ding, L., Fan, X., Pankowicz, F. P., Zhang, Q.-Y., & Ding, X. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083303 · Cited by 61
Self-citationFang, C., Behr, M. J., Xie, F., Lu, S., Doret, M., Luo, H., Yang, W., Aldous, K. M., Ding, X., & Gu, J. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.10.014 · Cited by 59
“Since CPR is the obligatory electron donor for all microsomal P450-dependent activities (Black and Coon, 1987), loss of the Cpr gene led to abolishment of nearly 95% of hepatic microsomal P450 activities in the liver-Cpr-null mice, but in the extrahepatic tissues P450 activities were not affected (Gu et al., 2003).”
BackgroundMethodResultInfluentialSelf-citationPinto, J. T., & Cooper, A. J. L. (2014) · Advances in Nutrition · doi:10.3945/an.113.005181 · Cited by 67
“Studies using mouse knockout models for CPR indicate that the flavoenzyme is indispensable for cholesterogenesis and steroidogenesis because no other electron donor is capable of providing reducing equivalents to the microsomal CYP heme proteins (43).”
MethodP450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia
Flück, C. E., & Miller, W. L. (2006) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000236395.71956.5c · Cited by 57
Bardowell, S. A., Ding, X., & Parker, R. S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m030734 · Cited by 57
Self-citationFlück, C. E., Nicolo, C., & Pandey, A. V. (2007) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00520.x · Cited by 55
Genetic variation in human P450 oxidoreductase
Miller, W. L., Huang, N., Agrawal, V., & Giacomini, K. M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.017 · Cited by 54
Wang, Y., Chen, Q., Wu, S., Sun, X., Yin, R., Ouyang, Z., Yin, H., & Wei, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.009 · Cited by 56
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Clinical and Biochemical Consequences of P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2011) · Endocrine Development · doi:10.1159/000321221 · Cited by 52
Zhang, Q., Fang, C., Zhang, J., Dunbar, D. A., Kaminsky, L. S., & Ding, X. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025429 · Cited by 50
“Genotype analyses for the Cre transgene and the Cpr allele were performed as described previously (Gu et al., 2003; Wu et al., 2003).”
BackgroundMethodSelf-citationKwon, D., Kim, S., & Correia, M. A. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.002 · Cited by 54
Emmerstorfer‐Augustin, A., Wimmer‐Teubenbacher, M., Wriessnegger, T., Leitner, E., Müller, M., Kaluzna, I. A., Schürmann, M., Mink, D., Zellnig, G., Schwab, H., et al. (2015) · Biotechnology Journal · doi:10.1002/biot.201400780 · Cited by 50
Zhang, X., Li, L., Ding, X., & Kaminsky, L. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038836 · Cited by 51
“…drug metabolism in patients is supported by several lines of data, including the impact of Por gene knockout on drug clearance in mouse models (Gu et al., 2003; Henderson et al., 2003; Zhang et al., 2009), positive correlations between POR activity and P450-mediated drug metabolism activities…”
BackgroundResultSelf-citationChen, X., Pan, L. Q., Naranmandura, H., Zeng, S., & Chen, S. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038495 · Cited by 53
He, Y., Lian, W., Ding, L., Fan, X., Ma, J., Zhang, Q.-Y., Ding, X., & Lin, G. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02921-0 · Cited by 43
Self-citationA novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism
Barzi, M., Pankowicz, F. P., Zorman, B., Liu, X., Legras, X., Yang, D., Borowiak, M., Bissig-Choisat, B., Sumazin, P., Li, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00049-x · Cited by 42
Elens, L., Nieuweboer, A. J. M., Clarke, S. J., Charles, K. A., de Graan, A. M., Haufroid, V., van Gelder, T., Mathijssen, R. H. J., & van Schaik, R. H. N. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835dc113 · Cited by 46
Yang, G., Fu, Z.-M., Chen, X., Yuan, H., Yang, H., Huang, Y., Ouyang, D., Tan, Z.-R., Tan, H., Huang, Z., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.004 · Cited by 45
Hepatic cytochrome P450s play a major role in monocrotaline-induced renal toxicity in mice
Yao, J., Li, C., Gong, L., Feng, C., Li, C.-Z., Gao, M., Luan, Y., Qi, X., & Ren, J. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.145 · Cited by 40
Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine
Zhang, Q.-Y., Kaminsky, L. S., Dunbar, D. A., Zhang, J., & Ding, X. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016543 · Cited by 40
“In the LCN mouse, Cpr expression is abolished in essentially all hepatocytes, but it is normal in other tissues (Gu et al., 2003).”
InfluentialSelf-citationCharacterizing Proteins of Unknown Function: Orphan Cytochrome P450 Enzymes as a Paradigm
Guengerich, F. P., Tang, Z., Salamanca-Pinzon, S. G., & Cheng, Q. (2010) · Molecular Interventions · doi:10.1124/mi.10.3.6 · Cited by 45
Kumar, R., Mota, L. C., Litoff, E. J., Rooney, J. P., Boswell, W. T., Courter, E., Henderson, C. M., Hernandez, J. P., Corton, J. C., Moore, D. D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174355 · Cited by 44
“These include P450 oxidoreductasenull mice (HRN or POR-null) that lack all CYP activity because they lack this crucial cofactor [35, 36], and the Cyp2a(4/5)bgs-null mouse model that lacks a 1.”
Pandey, A. V., Flück, C. E., Huang, N., Tajima, T., Fujieda, K., & Miller, W. L. (2004) · Endocrine Research · doi:10.1081/erc-200044134 · Cited by 39
Wu, X., Barnhart, C. D., Lein, P. J., & Lehmler, H. (2014) · Environmental Science & Technology · doi:10.1021/es504766p · Cited by 42
Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models
Jiang, X.-L., Gonzalez, F. J., & Yu, A. (2010) · Drug Metabolism Reviews · doi:10.3109/03602532.2010.512294 · Cited by 41
“These Cpr genetically modified mouse models were used to investigate the physiological role of Cpr (Gu et al., 2003; Wu et al., 2005; Mutch et al., 2006) and the importance of Cpr in the metabolic clearance or detoxification of many xenobiotic drugs (Pass et al., 2005; Henderson et al., 2006; Weng et al., 2007; Fang e…”
BackgroundMethodInfluentialXie, F., Zhou, X., Genter, M. B., Behr, M., Gu, J., & Ding, X. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037895 · Cited by 37
“, 2010), and 2) the liver-Cprnull (LCN) mouse (Gu et al., 2003), which has been found valuable for differentiating between hepatic and extrahepatic P450 contributions to systemic drug clearance and target tissue toxicities (e.”
BackgroundSelf-citationMultigene Predictors of Tacrolimus Exposure in Kidney Transplant Recipients
Pulk, R., Schladt, D. P., Oetting, W. S., Guan, W., Israni, A. K., Matas, A. J., Remmel, R. P., Jacobson, P. A., & for the DeKAF Investigators (2015) · Pharmacogenomics · doi:10.2217/pgs.15.42 · Cited by 39
Human germline hedgehog pathway mutations predispose to fatty liver
Guillen-Sacoto, M. J., Martinez, A. F., Abe, Y., Kruszka, P., Weiss, K., Everson, J. L., Bataller, R., Kleiner, D. E., Ward, J. M., Sulik, K. K., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.008 · Cited by 36
“oxidation (Cyp3a5, Cyp2c9, Sult2a1, Sult2a2, Acot2) [38-41]; lipid mobilization (Pltp and Fabp7) [42, 43]; and glucose metabolism (Pdk4, Pfkfb3) [44, 45], indicating that Hh signaling disruption affects hepatic energy metabolism.”
BackgroundFinn, R. D., McLaren, A. W., Carrie, D., Henderson, C. J., & Wolf, C. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121780 · Cited by 35
“The conditional deletion of POR in the liver using Por/Cre mice generated identical phenotypic changes to those observed when Cre recombinase was expressed using the rat albumin promoter (Gu et al., 2003; Henderson et al., 2003a), which included the increased expression of P450 isozymes.”
MethodFang, C., & Zhang, Q. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167742 · Cited by 35
“, 2009) and liver-Cpr-null (Gu et al., 2003) mice (both”
BackgroundMethodSelf-citationLin, Y., Yao, Y., Liu, S., Wang, L., Moorthy, B., Xiong, D., Cheng, T., Ding, X., & Gu, J. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.05.005 · Cited by 35
“…Author M anuscript transgenic mice, several tissue-specific Cpr-null mouse models have been produced, including the liver-specific Cpr-null mouse (Gu et al., 2003), the lung-specific Cpr-null mouse (Weng et al., 2007), the cardiomyocyte-specific Cpr-null mouse (Fang et al., 2008a), the…”
InfluentialSelf-citationPharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy
Hu, L., Zhuo, W., He, Y., Zhou, H., & Fan, L. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328358d92b · Cited by 40
McCammon, K. M., Panda, S. P., Xia, C., Kim, J.-J. P., Moutinho, D., Kranendonk, M., Auchus, R. J., Lafer, E. M., Ghosh, D., Martasek, P., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716019 · Cited by 33
“A mouse model in which POR was conditionally deleted in hepatocytes showed a marked induction of liver CYPs (up to 5-fold depending upon age of the mice) (7) and heme oxygenase (up to 9-fold) (8), as a compensatory mechanism, indicating the reliance of these redox partners on POR for activity.”
BackgroundMethodCytochrome P450 Oxidoreductase Deficiency
Idkowiak, J., Cragun, D. L., Hopkin, R. J., & Arlt, W. (2009) · University of Washington, Seattle eBooks · Cited by 33
Yablokov, E. O., Sushko, T. A., Ershov, P. V., Florinskaya, A. V., Gnedenko, O. V., Shkel, T. V., Grabovec, I. P., Strushkevich, N. V., Kaluzhskiy, L. A., Usanov, S. A., et al. (2019) · Biochimie · doi:10.1016/j.biochi.2019.04.020 · Cited by 32
Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes
Vonada, A., Tiyaboonchai, A., Nygaard, S. C., Posey, J., Peters, A. M., Winn, S. R., Cantore, A., Naldini, L., Harding, C. O., & Grompe, M. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg3047 · Cited by 31
“Second, liver-specific Cypor knockout mice show normal development and reproduction, although they show impaired drug metabolism and hepatic lipid accumulation (24, 25).”
BackgroundGeneration and Characterization of a Novel Cyp2a(4/5)bgs-Null Mouse Model
Wei, Y., Li, L., Zhou, X. M., Zhang, Q.-Y., Dunbar, A. Y., Liu, F., Kluetzman, K., Yang, W., & Ding, X. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048736 · Cited by 35
“…in the Cyp2a(4/5)bgs-null mouse (;2-fold) with those seen previously in the liver-Cpr-null mouse in which all hepatic microsomal P450 enzymes were inactivated [.10-fold (Gu et al., 2003)], we can further conclude that other P450 enzymes also make important contributions to pentobarbital clearance.”
BackgroundSelf-citationThe Disruption of Hepatic Cytochrome P450 Reductase Alters Mouse Lipid Metabolism
Mutch, D. M., Klocke, B., Morrison, P., Murray, C. A., Henderson, C. J., Seifert, M., & Williamson, G. (2007) · Journal of Proteome Research · doi:10.1021/pr0700448 · Cited by 31
Fan, X., Li, H., Ding, X., & Zhang, Q.-Y. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086678 · Cited by 32
“Two- to 3-month-old male LCN mice (Gu et al., 2003), IECN mice (Zhang et al., 2009), and their corresponding wild-type littermates were used for the study.”
BackgroundMethodSelf-citationElectron Transfer Pathways in Cholesterol Synthesis
Porter, T. D. (2015) · Lipids · doi:10.1007/s11745-015-4065-1 · Cited by 34
“Two groups reported the liver-specific (conditional) deletion of the cytochrome P450 reductase gene in 2003 [22, 23].”
BackgroundPolymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy
Gong, L., Zhang, C., Lv, J., Zhou, H., & Fan, L. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000297 · Cited by 35
Jan, Y.-H., Richardson, J. R., Baker, A. A., Mishin, V. M., Heck, D. E., Laskin, D. L., & Laskin, J. D. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.07.023 · Cited by 34
“For example, liver specific deletion or conditional hepatic knockout of CPR decreases liver CYP activity and suppresses metabolism of a number of drugs and toxins including pentobarbital and acetaminophen (Gu et al., 2003; Henderson et al., 2003; Riddick et al., 2013).”
BackgroundFukami, M., Nagai, T., Mochizuki, H., Muroya, K., Yamada, G., Takitani, K., & Ogata, T. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.03.023 · Cited by 30
“abnormalities in the extra-hepatic organs including caudal regions, despite probably increased plasma atRA values because of impaired atRA inactivation in the liver [23].”
Kim, S., Wang, Y., Nabavi, N., Liu, Y., & Correia, M. A. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1195403 · Cited by 36
“Accordingly, genetic deletion of cytochrome P450 reductase (CPR), the sine qua non P450 redox partner, and consequent abolition of P450 oxidative function indeed results in the elevation of P450 hepatic content, most likely via protein stabilization (Gu et al., 2003; Henderson et al., 2003).”
BackgroundP450 Oxidoreductase Deficiency: A New Disorder of Steroidogenesis
Miller, W. L., Huang, N., Pandey, A. V., Flück, C. E., & Agrawal, V. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1336.012 · Cited by 39
History of Adrenal Research: From Ancient Anatomy to Contemporary Molecular Biology
Miller, W. L., & White, P. C. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac019 · Cited by 35
Fang, C., Gu, J., Xie, F., Behr, M. J., Yang, W., Abel, E. D., & Ding, X. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021881 · Cited by 29
“Studies using the liver-Cpr-null mice, in which the liver microsomal CPR levels were reduced by 95% from wild-type levels, revealed significant roles of hepatic CPR-dependent enzymes not only in cholesterol biosynthesis but also in systemic xenobiotic disposition and hepatic chemical toxicity (Gu et al., 2003).”
BackgroundMethodSelf-citationThe key role of gut–liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity
He, Y., Ma, J., Fan, X., Ding, L., Ding, X., Zhang, Q.-Y., & Lin, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.013 · Cited by 31
Self-citationLi, Z., Chadalapaka, G., Ramesh, A., Khoshbouei, H., Maguire, M., Safe, S., Rhoades, R. E., Clark, R., Jules, G., McCallister, M., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr261 · Cited by 29
Generation and Characterization of a CYP2C11-Null Rat Model by Using the CRISPR/Cas9 Method
Wei, Y., Yang, L. C., Zhang, X., Sui, D., Wang, C.-S., Wang, K., Shan, M., Guo, D., & Wang, H. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078444 · Cited by 29
“Each lane was loaded with 5-mg liver microsomal protein from an individual rat (Gu et al., 2003).”
Method
Metadata
- Authors
- Gu, J., Weng, Y., Zhang, Q.-Y., Cui, H., Behr, M., Wu, L., Yang, W., Zhang, L., & Ding, X.
- Affiliations
- New York State Department of Health (US)
- Corresponding author
- Ding, Xinxin
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 28
- Pages
- 25895-25901
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1983773316
- Semantic Scholar
- e15f23ec26086915cba1a6a0a30d82a5ebee81de
- Cited by
- 214
- References
- 54
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 4 · 2022: 13 · 2021: 9 · 2020: 3 · 2019: 11 · 2018: 8 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 15 · 2013: 14 · 2012: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6302 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (ES07462)
- National Institute of Environmental Health Sciences (R01ES007462, ES 07462)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- NADPH-cytochrome P450 reductase, liver-specific knockout, cytochrome P450 induction, heme oxygenase-1, heme oxygenase-2, hepatic lipidosis, cholesterol homeostasis, drug clearance, microsomal enzymes, biotransformation, liver microsomes
- MeSH terms
- Alleles, Animals, Body Weight, Cholesterol, Epoxide Hydrolases, Female, Genotype, Heme Oxygenase (Decyclizing), Homozygote, Liver, Male, Membrane Proteins, Mice, Transgenic, Microsomes, Liver, Models, Genetic, NADPH-Ferrihemoprotein Reductase, Organ Size, RNA, Sex Factors, Time Factors, Immunoblotting, Gene Expression Regulation, Enzymologic, Polymerase Chain Reaction, Gene Deletion, Mice, Heme Oxygenase-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.